Mycobacterium tuberculosis Complex and Rifampin Resistance, PCR, Non‑Sputum
Use
Globally, about 2 billion people are infected with Mycobacterium tuberculosis complex (MTB). In 2010, 8.8 million people developed active disease and 1.4 million people died due to the illness. In the United States in 2012, 9,951 new cases of tuberculosis were reported (3.2 cases per 100,000) with 536 deaths attributed to TB infections. Treatment regimens are typically effective but MTB strains resistant to first-line drugs require tailored therapy. Rifampin resistance often indicates multidrug resistant TB (MDR‑TB), which includes resistance to rifampin and isoniazid. In the U.S., rifampin resistance occurs in approximately 1.8% of strains, and of those, about 90% are also resistant to isoniazid.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
3‑5 mL
Minimum Volume
Not provided
Container
Sterile Container
Collection Instructions
3‑5 mL bronchia brush/wash, tracheal aspirate or urine. 0.5‑1 mL body fluid, CSF or tissue in sterile container acceptable; for tissue add a small amount of sterile, non‑bacteriostatic saline to container (no fixative or preservative).
Causes for Rejection
Specimens received in formalin and/or alcohol
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 Hours |
| Refrigerated | 7 Days |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant